Caffeine
Also known as Caffeine, 1,3,7-Trimethylxanthine, Methyltheobromine, Theine
“CIR Expert Panel says: safe as used in cosmetics.”
The CIR Expert Panel concluded in 2024 that Caffeine, Theobromine, and Theophylline are safe in cosmetics in present practices of use and concentration (Cherian et al., Int J Toxicol 43(4_suppl):42-77, 2024; PMID 39049435), confirming the December 2018 final report listed in the CIR Quick Reference Table. The 2018 VCRP survey reports caffeine in 1033 cosmetic formulations (882 leave-on) at concentrations up to 6% in non-spray body and hand products and up to 1.5% in eye-area products. Otberg et al. (2007, PMID 17396054) demonstrated rapid follicular penetration of topical caffeine (within 2 minutes via shampoo), and a 6-week clinical study with 3.5% water-soluble caffeine showed a measurable but modest 19.8% improvement in cellulite visual scale score (Byun et al. 2015, PMID 26082579).
CIR Expert Panel concluded caffeine is safe in cosmetics in present practices of use and concentration (PMID 39049435, 2024; final report Dec 2018)
Skin-conditioning agent and fragrance ingredient per CIR functional designation; commonly used in eye-area products for de-puffing and in body products for anti-cellulite/slimming claims
Demonstrated dermal/follicular penetration: Otberg et al. (2007) showed caffeine penetrates the skin via the hair follicle pathway within 2 minutes of topical application, validating the delivery route
Modest but measurable clinical improvement in cellulite appearance: 3.5% caffeine slimming cream reduced visual cellulite score by 19.8% at 6 weeks with only mild, transient adverse effects (Byun et al. 2015, PMID 26082579)
Antioxidant and vasoconstrictor activity supports use in eye-area products to reduce the appearance of puffiness and dark circles
- · IARC classified caffeine as not classifiable as to its carcinogenicity to humans (Group 3) — inadequate evidence; this is a 'no signal' finding, not a positive carcinogenicity flag
Pharmacological-vs-cosmetic dose distinction: although caffeine is pharmacologically active orally (CNS stimulant, diuretic, vasoconstrictor), dermal absorption from cosmetic use yields systemic exposure orders of magnitude below pharmacological thresholds; the CIR Panel found no safety concern at present cosmetic use concentrations (up to 6% leave-on)
Cellulite efficacy evidence is limited: clinical improvements are modest (~20% on visual scale at 3.5% caffeine over 6 weeks) and the literature notes that larger trials are required to confirm efficacy
CIR Quick Reference Table (September 2022) — Caffeine row: Finding=S, Citation=Final Report 12/2018 Available from CIR
“Caffeine S Final Report 12/2018 Available from CIR”— QuickReferenceTable_AllConclusionTypes.pdf, p. 83